Dataset Information

Route choice in pedestrians: determinants for initial choices and revising decisions.

ABSTRACT: In moving pedestrian crowds, the distribution of individuals over different available routes emerges from the decisions of individuals that may be influenced by the actions of others. Understanding this phenomenon not only is important for research into collective behaviour, but also has practical applications for building safety and event management. Here, we study the mechanisms underlying pedestrian route choice, focusing on how time-independent information, such as path lengths, and time-dependent information, such as queue lengths, affect both initial decisions and subsequent changes in route choices. We address these questions using experiments with nearly 140 volunteers and an individual-based model for route choice. Crucially, we consider a wide range of route choice scenarios. We find that initial route choices of pedestrians achieve a balanced usage of available routes. Our model suggests that pedestrians performing trade-offs between exit widths and predicted exit crowdedness can explain this emergent distribution in many contexts. Few pedestrians adjust their route choice in our experiments. Simulations suggest that these decisions could be explained by pedestrians comparing estimates of the time it would take them to reach their target using different routes. Route choice is complex, but our findings suggest that conceptually simple behaviours may explain many movement decisions.

SUBMITTER: Liao W

PROVIDER: S-EPMC5332561 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Route choice in pedestrians: determinants for initial choices and revising decisions.

Liao Weichen W Kemloh Wagoum Armel U AU Bode Nikolai W F NW

Journal of the Royal Society, Interface 20170201 127

In moving pedestrian crowds, the distribution of individuals over different available routes emerges from the decisions of individuals that may be influenced by the actions of others. Understanding this phenomenon not only is important for research into collective behaviour, but also has practical applications for building safety and event management. Here, we study the mechanisms underlying pedestrian route choice, focusing on how time-independent information, such as path lengths, and time-dep ...[more]

PMID: 28228538

Similar Datasets

Project description:PurposeTo assess how patient choices (out-of-pocket costs, insurance plan, geographic region) impact initiation of therapy for diabetic macular edema (DME).DesignRetrospective cohort study using administrative medical claims data from a large, national insurer.ParticipantsAll patients newly diagnosed with DME from 2013 through 2016 were observed for 90 days after diagnosis or until first treatment was received.MethodsMultivariate logistic regression was used to create odds ratios comparing different baseline demographic and patient-related factors.Main outcome measuresThe primary outcome was the odds of receiving the different possible initial treatments for DME (anti-vascular endothelial growth factor [VEGF], focal laser treatment, steroids, or observation), no treatment, and not following up.ResultsOf the 6220 newly diagnosed DME patients, 3010 (48.4%) underwent a follow-up examination within 90 days of diagnosis, and of those, 1453 patients (48.3%) received treatment in the observation window, including 614 (20.4%) with bevacizumab, 191 (6.3%) with ranibizumab or aflibercept, 560 (18.6%) with focal laser, 38 (1.3%) with steroid injection, and 50 (1.7%) with an injection of an unspecified drug. Having a copay (vs. $0) lowered the odds of receiving any treatment (odds ratio [OR] = 0.60; 95% confidence interval [CI], 0.51-0.71; P < 0.001) and of receiving each treatment individually (anti-VEGF treatment: OR = 0.72; 95% CI, 0.59-0.88; bevacizumab: OR = 0.73; 95% CI, 0.59-0.91; ranibizumab or aflibercept: OR, 0.70; 95% CI, 0.49-0.99; focal laser: OR = 0.44; 95% CI, 0.35-0.55; P < 0.001). Contrary to having a copay, having a high deductible and type of insurance plan were not associated with initiating treatment (P > 0.41 for all comparisons). Patients in the Northeast showed lower odds of initiating anti-VEGF treatment (OR = 0.60; 95%CI, 0.44-0.82; P < 0.001) and specifically bevacizumab (OR = 0.47; 95% CI, 0.33-0.67; P < 0.001). Furthermore, Northeast patients who were treated with anti-VEGF showed a higher odds of receiving ranibizumab or aflibercept compared with bevacizumab (OR = 2.39; 95% CI, 1.31-4.37; P < 0.001). Southern Midwest patients showed a higher odds of treatment (anti-VEGF: OR = 1.35; 95%CI, 1.02-1.77; P < 0.001; bevacizumab: OR = 1.40; 95% CI, 1.04-1.87; focal laser: OR = 1.39; 95% CI, 1.01-1.89; P < 0.001).ConclusionsPatient choices such as copays and where they live are important factors in determining the initial choice of treatment for DME.

Dataset Information

Route choice in pedestrians: determinants for initial choices and revising decisions.

Publications

Route choice in pedestrians: determinants for initial choices and revising decisions.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure